EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC)

被引：0
|
作者：
Nazha, Aziz [1 ]
Jabbour, Elias [1 ]
Cortes, Jorge E. [1 ]
O'Brien, Susan [1 ]
Shan, Jenny [1 ]
Garcia-Manero, Guillermo [1 ]
Quintas-Cardama, Alfonso [1 ]
Kantarjian, Hagop M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1609 / 1609
页数：1
相关论文
共 50 条
  • [21] Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP)
    Cortes, Jorge
    O'Brien, Susan
    Borthakur, Gautam
    Jones, Dan
    Ravandi, Farhad
    Koller, Charles
    Mesina, Ofelia
    Ferrajoli, Alessandra
    Shan, Jianqin
    Kantarjian, Hagop
    BLOOD, 2008, 112 (11) : 74 - 74
  • [22] EFFICACY OF DASATINIB IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED CHRONIC MYELOGENOUS LEUKEMIA (CML) IN EARLY CHRONIC PHASE (CML-CP)
    Cortes, J.
    Borthakur, G.
    Jones, D. M.
    O'Brien, S.
    Koller, C. A.
    Nicaise, C.
    Garcia-Manero, G.
    Ferrajoli, A.
    Kantarjian, H. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 349 - 349
  • [23] Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)
    Cortes, Jorge
    O'Brien, Susan
    Jones, Dan
    Koller, Charles
    Borthakur, Gautam
    Nicaise, Claude
    Henderson, Laverne
    Ferrajoli, Alessandra
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 17A - 17A
  • [24] Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP)
    Cortes, Jorge
    Borthakur, Gautam
    O'Brien, Susan
    Jones, Dan
    Jabbour, Elias
    Ravandi, Farhad
    Koller, Charles
    Walker, Brenda
    Shan, Jenny
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 143 - 143
  • [25] Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).
    Gore, Lia
    Kearns, Pamela
    Lee, Maria Lucia
    De Souza, Carmino Antonio
    Bertrand, Yves
    Hijiya, Nobuko
    Stork, Linda C.
    Chung, Nack-Gyun
    Cardenas-Cardos, Rocio
    Saikia, Tapan
    Fagioli, Franca
    Seo, Jong-Jin
    Landman-Parker, Judith
    Lancaster, Donna
    Place, Andrew E.
    Rabin, Karen R.
    Sacchi, Mariana
    Swanink, Rene
    Zwaan, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)
    Borthakur, G.
    Kantarjian, H. M.
    O'Brien, S. M.
    Jones, D.
    Koller, C.
    Nicaise, C.
    Garcia-Manero, G.
    Ferrajoli, A.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Impact of Mutations in Blood Cancer-Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors ( TKIs) in the Ascembl Trial
    Branford, Susan
    Hochhaus, Andreas
    Mauro, Michael
    Minami, Yosuke
    Rea, Delphine
    Boquimpani De Moura Freitas, Carla Maria
    Serrano-Fernandez, Pablo
    Obourn, Vanessa
    Bruederle, Andreas
    Espurz, Noemi
    Hughes, Timothy P.
    BLOOD, 2023, 142
  • [28] Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs)
    Hughes, Timothy
    Mauro, Michael
    Kim, Dong-Wook
    Cortes, Jorge
    Rea, Delphine
    Minami, Hironobu
    Breccia, Massimo
    DeAngelo, Daniel
    Hochhaus, Andreas
    Goh, Yeow-Tee
    le Coutre, Philipp
    Lang, Fabian
    Cacciatore, Silvia
    Aimone, Paola
    Stenson, Laura
    Polydoros, Fotis
    Talpaz, Moshe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S235 - S235
  • [29] Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study
    Mauro, Michael
    Hochhaus, Andreas
    Hughes, Timothy
    Rea, Delphine
    Boquimpani, Carla
    Minami, Yosuke
    Apperley, Jane
    Garcia-Gutierrez, Valentin
    Kapoor, Shruti
    Espurz, Noemi
    Dhamal, Vishal
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S340 - S340
  • [30] Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US)
    Kota, Vamsi
    Maegawa, Rodrigo
    Latremouille-Viau, Dominick
    Jadhav, Kejal
    Rossi, Carmine
    Guerin, Annie
    Iorga, Serban
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S300 - S301
12345